BTIG analyst Amanda Murphy raised her price target on Buy-rated Editas Medicine (EDIT) to $33 from $30 and CRISPR Therapeutics (CRSP) to $49 from $43 as part of her first installment of a broader research note analyzing hiring trends in the gene therapy space. The analyst notes that the latter is “aggressively adding process development/CMC/Tech capabilities in cell therapy, including late stage process development resources”, which may suggest that the company is “farther along” in the development of CTX110. Murphy also observes that Editas Medicine appears to be “shifting focus to engineered stem cell therapy while still investing in allo CAR-T and potentially new in vivo indications and delivery vectors.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.